ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1223

Reduced Antibody Titers Against Pertussis in Rheumatoid Arthritis

Caitlyn L. Holmes1, Chloe Peyton2, Amy Bier3, Tobias Donlon2, Christie M. Bartels4 and Miriam A. Shelef5,6, 1University of Wisconsin - Madison, Madison, WI, 2University of Minnesota Medical School, Minneapolis, MN, 3Stritch School of Medicine of Loyola University Chicago, Chicago, IL, 4Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI, 5Department of Medicine, Division of Rheumatology, University of Wisconsin - Madison, Madison, WI, 6William S. Middleton Memorial Veterans Hospital, Madison, WI

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Antibodies, rheumatoid arthritis (RA) and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Infection-related Rheumatic Disease Poster

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with rheumatoid arthritis, an autoimmune disease affecting ~1% of the population, have an increased risk of infection. Interestingly, data are mixed for response to vaccination with rheumatoid arthritis patients showing a reduced response to some vaccine antigens, but relatively normal antibody titers in response to others, like the highly efficacious tetanus vaccine. Little is known about the response to pertussis vaccination in rheumatoid arthritis, a concerning omission given the relatively low efficacy of the pertussis vaccine, the rise in pertussis infections in the last 20 years, and the increased susceptibility of rheumatoid arthritis patients to infection. The purpose of this study is to determine if pertussis titers are reduced in vaccinated subjects with rheumatoid arthritis versus controls as well as to determine if clinical factors in rheumatoid arthritis, including the use of immune suppressing medications, correlate with pertussis titers.

Methods: Serum from 98 subjects with seropositive rheumatoid arthritis not using rituximab (a B cell depleting drug) and 77 controls, all vaccinated within 10 years of serum collection with the Tdap (tetanus, diphtheria, and pertussis) vaccine, were selected from our biorepository. Serum was subjected to enzyme-linked immunosorbent assay to detect IgG titers against pertussis and tetanus toxoid. Titers were compared by unpaired t-test and the rates of immunity based on manufacturer cut-offs were compared by a Fisher’s exact test. Univariate and multivariate logistic regression was used to identify clinical factors that correlate with pertussis titers. A p value <0.05 was considered significant.

Results: Subjects with rheumatoid arthritis had significantly lower IgG titers against pertussis, but not tetanus, compared to controls and fewer rheumatoid arthritis subjects were immune to pertussis. At less than 5 years post-vaccination, there was no significant difference in pertussis titers between rheumatoid arthritis patients and controls. However, at 5-10 years post-vaccination, rheumatoid arthritis patients had 50% lower titers than controls and fewer rheumatoid arthritis subjects met immune thresholds. Multivariate regression demonstrated that rheumatoid arthritis, female sex, and longer length of time since vaccination correlated with lower than median pertussis titers. Interestingly, the use of leflunomide or methotrexate at the time of serum collection correlated with higher and lower than median pertussis titers, respectively. No correlation was seen between TNF-inhibiting medications and pertussis titer.

Conclusion: Patients with rheumatoid arthritis have lower IgG titers against pertussis, especially 5-10 years post-vaccination. Reduced titers could be due to the relatively low efficacy of the pertussis vaccine, a dysregulated immune system in rheumatoid arthritis, and/or the use of certain medications. Future studies are needed to determine the mechanism for reduced immunity to pertussis, if more frequent vaccination would improve titers against pertussis, and if susceptibility to pertussis infection is increased in patients with rheumatoid arthritis.


Disclosure: C. L. Holmes, None; C. Peyton, None; A. Bier, None; T. Donlon, None; C. M. Bartels, Pfizer, Inc., 2; M. A. Shelef, None.

To cite this abstract in AMA style:

Holmes CL, Peyton C, Bier A, Donlon T, Bartels CM, Shelef MA. Reduced Antibody Titers Against Pertussis in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/reduced-antibody-titers-against-pertussis-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/reduced-antibody-titers-against-pertussis-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology